Fu and colleagues69 demonstrated that FHL1 is a novel and powerful prognostic indicator and potential therapeutic target in acute myeloid leukemia (AML), including non-acute promyelocytic leukemia (non-APL) AML and cytogenetically normal AML (CN-AML), by comparing genome-wide expression and clinical data from three independent AML datasets. Here, FHL1 is linked to acute promyelocytic leukemia.